The UK and US have hammered out a important trade agreement that will maintain zero levies on British medicine products going into the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to raise funding on medicines through the NHS. This commitment guarantees that import taxes on these crucial products will be held at zero for a period of the next three years.
This agreement is in response to earlier threats to dramatically increase tariffs on patented pharmaceutical imports, with increases mentioned as high as double the cost.
"This agreement between the United Kingdom reinforces the worldwide climate for new treatments and establishes long-overdue balance to American-British medicine commerce," a statement declared.
Trade Importance
Pharmaceuticals represent one of the the United Kingdom's biggest export categories to the US, which is clearly the biggest buyer for leading British pharmaceutical firms.
Statistics show that in the year leading up to September, the UK shipped medicines valued at billions to the US. This figure accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal secures work, stimulates capital expenditure and paves the way for the UK to become a global hub for medical research," a government official commented.
Specific UK Commitments
The pact includes several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise total public funding on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, rebates were more than twenty percent.
Industry Background
The deal takes place against a ongoing row between the drug companies and the ministers over spending levels and NHS adoption.
These tensions were exacerbated by claims that American customers were charged a premium for the equivalent treatments than patients in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been directed toward American operations.
A senior figure acknowledged that the NHS must spend more on treatments, noting that its spending on drugs had declined as a percentage of its resources over the previous ten-year period.
